Florida International University is cognizant of the impacts that the COVID-19 outbreak has on the FIU community as well as the rest of the state and nation. The University, and its Emergency Operations Center (EOC), are actively monitoring and responding to the evolving situation to better understand the latest developments and provide continuing guidance to the FIU Research community. The FIU COVID-19 website contains important and current information for everyone in the University community.
ORED Announcements regarding COVID-19
Guidance to FIU Research Community in the Transition to Remote Work Beginning Monday, March 16, 2020
During this period of remote work, we expect that ORED and the University Graduate School (UGS) will remain fully operational, with the ability to submit, receive and manage research grants. (March 15, 2020… read more)
It is the intent of the Office of Research and Economic Development (ORED) to provide the University research community with guidance to help mitigate any potential impacts on research activities and guidance updates from our various funding agencies as they become available.
With the ongoing concern about the spread of this disease, laboratories and research facilities should begin to finalize and implement plans for the disruption to routine operations. Each laboratory or research facility is best positioned to implement plans that will meet their unique needs. This guidance is provided to facilitate the development of your plan.
The guidance provided herein is not intended to be all-inclusive and is based on what is known at this time. We will update the research community as the situation develops and more information becomes available. It is important that the entire FIU research community follow the University’s updates.
Research Continuity Guidance for Laboratories and Research Facilities
Assumptions that you can use for planning, based on a scenario with widespread COVID-19 communal transmission:
- A significant percentage of your laboratory workforce may be out sick or unable to come to work.
- Essential research infrastructure, such as power and telecommunications, will be maintained.
- Environmental Health and Safety (EHS) will maintain essential research support functions, although some lower-priority services may need to be curtailed (e.g., less frequent waste pick-up).
- The Animal Care Facility (ACF) will continue to operate under its pandemic response procedures. ACF users will be notified directly of any changes or updates to normal operations. Any specific questions should be directed to Dr. Horatiu Vinerean at horatiu.vinerean@fiu.edu.
- Orders for critical supplies may be delayed and/or unavailable. ORED can assist if researchers need help in locating supplies in case of shortages.
- Core facilities and other fee-for-service resources may experience disruptions of services.
Steps you can take now to ensure continuity of critical functions:
- Identify procedures and processes that require regular personnel attention (e.g., cell culture maintenance, animal studies).
- All laboratories and research facilities should forward contingency plans to Luis Salas at salasl@fiu.edu and Stephanie Mitjans at smitjans@fiu.edu so that they may be reviewed and followed.
- Assess and prioritize critical laboratory activities.
- Identify any research experiments that can be ramped down, curtailed, or delayed. Notify pre-award and funding agency program officers (if applicable) of such delays.
- Identify key personnel able to safely perform essential activities, and to ensure the integrity of your group’s research efforts.
- Provide a list of essential personnel and identifying information (Panther ID) that may need access during a potential shutdown so that they may be granted access to their research sites to Luis Salas at salasl@fiu.edu and Stephanie Mitjans at smitjans@fiu.edu.
- Ensure that you have access to emergency contact information for your critical staff, including cell phone numbers.
- Cross-train research staff to fill in for others who may be out sick or unable to come to work.
- Ensure staff have the appropriate training and required certifications.
- Ensure you are documenting critical step-by-step instructions in your Standard Operating Procedures (SOP).
- Coordinate with colleagues who have similar research activities to identify ways to ensure coverage of critical activities.
- Review contingency plans and emergency procedures with researchers and staff.
- Maintain sufficient inventory of critical supplies that may be impacted by shortages or global shipping delays.
- Communicate significant planned absences and/or lab closures to Luis Salas at salasl@fiu.edu and Stephanie Mitjans at smitjans@fiu.edu and key academic and administrative units.
- Prioritize. Depending upon the nature of your research, consider prioritizing work that can only be carried out in your research facility, and put off work amenable to remote support, such as data analysis. Stockpiling results and data now that could be analyzed remotely in the future is a potential option that might create future flexibility.
- Consider the steps needed to secure your research program in case of a long-term event that may prevent access to the campus or specific building.
Remote access:
- Ensure that those involved in research projects have access to information they need to carry out work remotely (e.g., access to literature, computers, existing datasets and research-related files, and meeting software, such as Zoom or Microsoft Teams).
- Test and update remote work technologies such as VPN and Zoom conferencing.
- Under no circumstances are researchers to take materials other than laptops, data storage devices, etc., offsite (e.g., to their homes). Ensure that no data or files with patient or participant identifying information is compromised and HIPAA and IRB regulations are followed.
Prevention of the spread of illness among your research group:
- The FIU Coronavirus Updates FAQ contains valuable information of steps to take for prevention and containment of the virus as well as CDC guidance.
Research continuity summary:
Advance planning will allow everyone in your research group to focus on their own efforts and work together as a team, rather than wonder how they and their team members are to proceed.
Quick Checklist:
- Identify critical lab operations.
- Identify critical lab personnel and ensure they know what to do in the event of suspended operations.
- Remind lab personnel of your communication plan or create one if not in place.
- Ensure remote access to files, data, servers, etc.
- Prioritize experiments.
- Cancel non-essential travel, and check University travel restrictions before making travel plans. Additionally, check FIU’s updated travel guidance.
Requests to Access Research Laboratories
During the current remote working environment, essential functions are typically those which must continue in order to ensure the health/safety of the university and ensure the continuity of key operations. In the current remote working environment for FIU, there will be essential functions that will require some level of presence in research laboratories, both wet and dry.
Our focus is on the health and safety of the university community. We are assessing requests for needs to maintain essential laboratory activities on a case-by-case basis. In order to better manage the decisions on allowed essential laboratory functions, we are providing a Request to Access Research Laboratories Form, which can be completed then submitted for review and approval. Completed Forms can be submitted to ORED to Associate Vice President Luis Salas at Luis.Salas@fiu.edu, with copies to Stephanie Mitjans at stephanie.mitjans@fiu.edu. When the Form is submitted to ORED, the respective Dean/Associate Dean needs to be copied in order to facilitate possible discussions between ORED and respective college.
In reviewing the needs of your lab or research team and completing the Form, it will be important to distinguish carefully between those functions that require access to campus, and those that can be conducted remotely. In most situations, we anticipate that only a subset of research personnel within a lab will require access to campus. As you complete the Form, provide information only for the personnel that needs access to campus.
Research Involving Biospecimens
Any research group that plans to handle/work with SARS-CoV-2 biospecimens (from COVID-19 patients) must first receive clearance from FIU’s Office of Environmental Health and Safety (EH&S) prior to beginning any such research.
If cleared by EH&S, all appropriate/applicable safety precautions and procedures would be established and subsequently followed by the laboratory that would be conducting this research. Such procedures would be specifically tailored to the research itself and the type(s) of SARS-CoV-2 samples that the lab will work with.
Travel Guidance and Visitor Policy
FIU Coronavirus Updates FAQ provides travel guidance due to the continued spread of COVID-19. Please continue to monitor University advisories on travel restrictions and see any specific agency guidance in the Guidance from Funding Agencies section.
Office of Research and Economic development ORED
We expect that the Office of Research and Economic (ORED) will remain fully operational, with the ability to submit, receive and manage research grants, even if most personnel are working remotely. Typically, federal agencies are flexible about deadlines under difficult circumstances beyond our control such as natural disasters or pandemic events. However, if federal agencies are officially closed, proposals will most likely remain in a queue, pending resumption of agency operations – as has been the case during federal budget-related shutdowns. ORED will post agency specific guidance as it becomes available. See Guidance from Funding Agencies section. All ORED personnel are working to ensure continuity of services for the research community.
Institutional Research Board (IRB)
Researchers should carefully review over their protocols to determine if modifications are needed as a result of the current COVID-19 situation (e.g., proposing alternative locations/methods for: consenting subjects, collecting data, communicating with subjects, storing data, etc.). If modification are needed to an ongoing IRB-approved research study, then the researcher must submit an amendment to the IRB and receive IRB approval before implementing the proposed modifications.
The only exception to the above requirement is if the change is designed to eliminate an apparent immediate hazard to subjects (45 CFR 46.103(b)(4)). If the researchers modify the research in order to eliminate apparent immediate hazards to subjects without prior IRB approval, then they must report this change to the IRB via an amendment within 5 business days of making the change.
Please note that placing a research project on hold will not require an IRB amendment (and will not be considered as a protocol deviation). However, IRB protocols that have been placed on hold will still need to be renewed by the IRB prior to the protocol’s expiration date.
Contact Christopher Grayson (graysonc@fiu.edu) if you have any questions.
Please also see the following guidance document from the NIH:
Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
University Graduate School (UGS)
The UGS personnel are following university guidance. While working remotely there is no anticipation of disruption to normal service. Continue to contact UGS personnel as needed. Staff will continue to monitor and respond to both office phone and email communications. Dissertation and thesis defenses will proceed as planned, with modified procedures that allow for remote presence of committee members and students. For questions regarding dissertation and thesis defenses and UGS operations, please reach out to us at ugs@fiu.edu or staff as indicated below:
Inquiries related to dissertation/thesis forms – Demi Moro, dmoro@fiu.edu
Inquiries related to ETD, formatting, Brandie Course, etd@fiu.edu
Inquiries related to change of degree, petitions, time-to-degree, DAS/GF, commencement, general inquiries – Ashley Mendez, amendez@fiu.edu
Inquiries related to GA’s – Betty Sigler – bsigler@fiu.edu
Inquiries related to fellowships – Claudia Balzán, ugsfellows@fiu.edu
Inquiries related to professional development workshops– Asfa Siddiqui, asiddiqu@fiu.edu
General inquiries, UGS operations – Karla Ortega, ortegak@fiu.edu
Guidance from Funding Agencies
Funding agencies are beginning to issue guidance regarding their operations and procedures in response to COVID-19. ORED will post any issued guidance and maintain current guidance as available. See list below for latest updates.
Admin. for Children and Families
Dept. of Defense Proposers & Awardees Impacted by COVID-19
Dept of Energy Accommodating Interruptions from COVID-19
Dept. of Energy Guidance for Financial Assistance Actions
DOJ Short-Term Relief 3/20/2020
Dept of Labor Susan Harwood Grantee 3/19/2020
Mellon Foundation COVID-19 Update
Miami-Dade Department of Cultural Affairs
NIH COVID-19 Guidance for Applicants and Grantees
NSF COVID-19 Guidance to the Research Community
Office of Management and Budget
Office of the Assistant Secretary for Health (OASH), Grants and Acquisitions Management (GAM)
Frequently Asked Questions
What ORED services will be available during this period?
ORED personnel are following university guidance. While working remotely there is no anticipation of disruption to normal service to the research community. Continue to contact ORED personnel as needed. Staff will continue to monitor and respond to both office phone and email communications. Communications will be sent via our listservs and posted on the ORED Novel Coronavirus (COVID-19) Resources website if there are changes.
I was planning to attend a conference and present the results of my funded research and the project budget allowed conference related expenses. The conference was cancelled. Will I be reimbursed for the expenses I have incurred?
Some agencies have begun to issue guidance regarding non-refundable travel, conferences and travel related expenses due to the coronavirus. See the Guidance from Funding Agencies section for specific sponsor guidance. For the most part the treatment of these charges are currently no different than in the past if travel had to be canceled for a compelling reason.
Documentation is critical when there are questions on change fees, cancellation fees, etc. These may be an allowable expense under extenuating circumstances provided there is a compelling and valid reason such as a canceled conference or medical emergency.
If you need to cancel a trip due to coronavirus, document that the trip was cancelled by the host or travel was suspended by the University. Include the memo from Dr. Furton on 3/10/2020 (or any subsequent memorandum) or notice of cancelation from the host of the conference as documentation on the expense report. If you have any questions, please contact your post-award administrator.
If the University approved your Travel Authorization request (TA), it will be reimbursed.
I am a PI working remotely on my funded research. Can my effort still be charged to the grant?
In general, yes, provided you remain engaged in your project. Current NIH and NSF prior approval requirements regarding disengagement and effort reductions remain in effect.
Can I charge trip cancellation insurance on my grant?
Trip cancellation insurance is typically unallowable on grants. Although airlines are not issuing refunds, most currently have procedures in place to provide limited time credits for future travel and are waiving the normal change fee. If you need assistance in canceling a trip or have any questions, contact your post-award administrator.
I am a PI on a grant and am required to work remotely due to University orders. Will I be able to charge my time and effort on the grant even though I working remotely?
Yes, if the effort is justified and related to programmed efforts.
I am quarantined due to the COVID-9 outbreak and am working from home and am unable to submit a grant proposal during the requisite deadlines. May I request an extension?
Most federal agencies, including NIH and NSF, do not grant prior approval for late submissions; however, there are existing policies that address extenuating circumstances. Current NIH guidance can be located at NOT-OD-15-039 and Special Exceptions to NSF’s Deadline Date Policy (PAPPG 19-1). We strongly encourage you to discuss your specific situation with your agency Program Official and see the Guidance from Funding Agencies section.
Where can I get more specific information on agency-specific information on disasters and emergencies such as the COVID-9 outbreak?
I am experiencing delays recruiting participants for my funded research study and/or cancellations of scheduled follow-up visits and it is negatively affecting the progress of my study. What should I do?
For programmatic issues affecting your study, we strongly recommend you speak with your agency Program Official or other sponsor contact. If any issues should persist, they may need to be reported in future progress reports, or you may need a No Cost Extension to complete your study. Please coordinate any such actions with ORED.
What is the Contingency Plan for Animal Care
ACF users will be notified directly in a separate communication of any changes or updates to normal ACF operations.
Funding Opportunities
American Heart Association
Rapid Response Grant
COVID-19 and Cardiovascular Impact
The American Heart Association (AHA) invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. Because of the urgency of this issue, innovative, highly impactful short-term proposals (9-12 months), which can show progress within the period of this award, are sought.
- Up to $100,000 per grant for 9 – 12 month project
- Deadline: April 6, 2020
National Heart, Lung and Blood Institute
Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
Notice Number: NOT-HL-20-757 https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html
To be eligible for either an Administrative Supplement or Urgent Competitive Revision, the parent award on which the supplement or revision application is based must:
- be an active NHLBI award (i.e., not be in an extension period) at the time the supplement or revision is awarded, and
- have sufficient time left to complete the studies proposed after the supplement or revision has been awarded within the existing project period.
All instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-18-591 or PA-18-935) must be followed.
- The project period will generally be limited to 1 year. Project periods up to 2 years will be considered only with strong justification.
- Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff listed on this NOSI well in advance of the grant receipt date to better determine appropriateness and interest of the NHLBI.
- Applications will be accepted on a rolling basis from March 17, 2020 through October 5, 2020 by 5:00 PM local time of the applicant organization.
National Institute of Allergy and Infectious Disease/National Institute of General Medical Sciences
- Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
Notice Number: NOT-AI-20-030
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html
Applications in response to this NOSI must be submitted using the following targeted funding opportunity:
- PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Further details can be found here: https://www.niaid.nih.gov/grants-contracts/urgent-award-mechanism.
- The funding instrument, or activity code, will be the same as the parent award.
- Please note: NOT-AI-20-030 is specific for PA-18-935. NIH grantees seeking additional funds for research responsive to the 2019-nCoV outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).
- The award project period of the Competitive Revision must not exceed two years.
- Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.
- Deadline: February 6, 2021
- Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
Notice Number: RFA-AI-20-028
https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html
- Significant partnership with industry required
- Letter of Intent due May 29. 2020
- Full Proposal due June 29, 2020
- Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)
Notice Number: PAR-18-781
https://grants.nih.gov/grants/guide/pa-files/PAR-18-781.html
- Letter of Intent Due August 4, 2020
- Full Proposal Due September 9, 2020
- Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)Notice Number: NOT-AI-20-031
https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html
In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address the following research areas of interest:
- Studies to identify optimal in vitroculture requirements and conditions;
- Development of reagents and assays for virus characterization;
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
- Studies to identify viral epitopes critical for binding neutralization;
- Studies to examine virus stability and persistence;
- Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;
- Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;
- Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
- Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;
- Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
- Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;
- Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and
- Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.
This notice applies to due dates on or after April 5, 2020 and subsequent receipt dates through April 5, 2021.
Submit applications for this initiative using one of the following funding opportunity announcements (FOAs) or any reissues of these announcement through the expiration date of this notice:
PA-19-052 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
PA-19-053 – NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp – Clinical Trial Optional)
PA-19-056 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
PA-19-272 – PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
PA-19-270 – PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)National Institute of Drug Abuse
Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047 https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html
Applications must be submitted using one of the following targeted funding opportunities:
- PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.
- PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.
- The funding instrument, or activity code, will be the same as the parent award.
- Application budgets are generally limited to no more than $100,000 direct costs per year. Should the proposed research require a higher budget, the applicant should consult with the program official assigned to the parent award and include a strong justification for the larger budget in the supplement application. The proposed budget must reflect the actual needs of the proposed project.
- The parent award must be active when the application is submitted. The project and budget periods must be within the currently approved project period for the existing parent award.
- Applications will be accepted on a rolling basis through March 31, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on April, 1, 2021.
National Institute of General Medical Sciences
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
Notice Number: NOT-GM-20-025
https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html
NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).
Applications in response to this NOSI must be submitted to PA-18-935 “Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement – Clinical Trial Optional)”, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. The activity code will be the same as that of the parent award.
- The award project period of the Competitive Revision must not exceed one year.
- Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.
- Competitive revisions to the R15, R21, and R00 may provide support above the established dollar limits for the parent grant award.
- The parent award must be active when the application is submitted.
- Applications will be accepted on a rolling basis from March 25, 2020 to February 5, 2021.
National Science Foundation
- RAPID Research on Coronavirus (COVID-19): https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.pdf
Program Number: NSF 20-052
- NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
- NSF encourages the research community to respond to this challenge through existing funding opportunities.
- It invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events.
- Requests for RAPID proposals may be for up to $200K and up to one year in duration.
- Deadline: Rolling
- Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)
Program Number: NSF 20-055
https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp
- The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) programor the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.
- Proposals may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream. To ensure availability of these computing resources, investigators must contact OAC prior to submission of the proposal.
- Deadline: Rolling
Department of Health and Human Services
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcements (BAA)
- Novel Coronavirus Medical Countermeasures
BAA-18-100-SOL-00003 Amendment 14
https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view
COVID-19 response related Areas of Interest includes:
- Diagnostic assay for human coronavirus using existing FDA-cleared platforms
- Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
- Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- COVID-19 Vaccine
- COVID-19 Therapeutics
- Immunomodulators or therapeutics targeting lung repair
- Pre-exposure and post-exposure prophylaxis
- Respiratory protective devices
- Ventilators
- Advanced Manufacturing Technologies
Quad Chart and White Paper Deadlines: April 30, 2020; July 31, 2020; October 31, 2020. Proposals submitted following invitation. Budget amounts not specified.
- New Topic under Area of Interest: COVID-19
BARDA Division of Research, Innovation & Ventures (DRIVe)
EZ-BAA-20-100-SOL-0002: https://beta.sam.gov/opp/f922eb52cec446c5875811752bf2d34c/view
Six areas of interest:
- Molecular Diagnostic Assay for SARS-CoV-2 virus on existing FDA-cleared platform
- Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
- Diagnostic Assay for detection of COVID-19 disease
- Nonclinical Model Development and Screening for SARS-CoV-2 virus
- COVID-19 Vaccine
- Advanced Manufacturing Technologies
White papers may be submitted until 2023. Proposals submitted following invitation. Budget amounts not specified.